Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma

Pathology Research and Practice

Volumn 205, Issue 6, 2009, Pages 386-394

  He, Mai ^a   Aisner, Seena ^a   Benevenia, Joseph ^b   Patterson, Francis ^b   Harrison, Lawrence E ^b   Hameed, Meera ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Cell cycle regulator; Dedifferentiation; Liposarcoma; p16; Promoter methylation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER GENETICS; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; DNA EXTRACTION; DNA METHYLATION; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPOSARCOMA; MALE; PROMOTER REGION; PROTEIN EXPRESSION; RECURRENT CANCER; TUMOR GENE;

ADULT; AGED, 80 AND OVER; CELL DEDIFFERENTIATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; SOFT TISSUE NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67349218110     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2008.12.009     Document Type: Article

References (33)

1. Adachi T., Oda Y., Sakamoto A., Saito T., Tamiya S., Masuda K., and Tsuneyoshi M. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component. Int. J. Surg. Pathol. 9 2 (2001) 99-109
2. Binh M.B., Sastre-Garau X., Guillou L., de Pinieux G., Terrier P., Lagacé R., Aurias A., Hostein I., and Coindre J.M. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am. J. Surg. Pathol. 29 10 (2005) 1340-1347
3. Belinsky S.A., Nikula K.J., Palmisano W.A., Michels R., Saccomanno G., Gabrielson E., Baylin S.B., and Herman J.G. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl. Acad. Sci. USA 95 20 (1998) 11891-11896
4. Chen J., Lin J., and Levine A.J. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1 2 (1995) 142-152
5. Dal Cin P., Kools P., Sciot R., De Wever I., Van Damme B., Van de Ven W., and Van den Berghe H. Cytogenetic and fluorescence in situ hybridization investigation of ring chromosomes characterizing a specific pathologic subgroup of adipose tissue tumors. Cancer Genet. Cytogenet. 68 2 (1993) 85-90
6. Dei Tos A.P., Piccinin S., Doglioni C., Vukosavljevic T., Mentzel T., Boiocchi M., and Fletcher C.D. Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. Am. J. Pathol. 151 6 (1997) 1531-1539
7. Di Vinci A., Perdelli L., Banelli B., Salvi S., Casciano I., Gelvi I., Allemanni G., Margallo E., Gatteschi B., and Romani M. p16(INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int. J. Cancer. 114 3 (2005) 414-421
8. Enterline H.T., Culberson J.D., Rochlin D.B., and Brady L.W. Liposarcoma. A clinical and pathological study of 53 cases. Cancer 13 (1960) 932-950
9. Fahraeus R., Paramio J.M., Ball K.L., Lain S., and Lane D.P. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr. Biol. 6 1 (1996) 84-91
10. Fletcher C.D., Akerman M., Dal Cin P., de Wever I., Mandahl N., Mertens F., Mitelman F., Rosai J., Rydholm A., Sciot R., Tallini G., van den Berghe H., van de Ven W., Vanni R., and Willen H. Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Am. J. Pathol. 148 2 (1996) 623-630
11. Hameed M.R., Lin T.Z., Coffman F., Cohen M.C., Fernandes H., Aviv H., Benevenia J., Aisner S.C., and Cohen C. Gene expression analysis of a dedifferentiated liposarccoma - differences between high and low grade areas: analysis of two cases and literature review. J. Musculoskeletal Res. 9 1 (2005) 9-20
12. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93 18 (1996) 9821-9826
13. Hong S.M., Choi J., Ryu K., Ro J.Y., and Yu E. Promoter hypermethylation of the p16 gene and loss of its protein expression is correlated with tumor progression in extrahepatic bile duct carcinomas. Arch. Pathol. Lab. Med. 130 1 (2006) 33-38
14. Hostein I., Pelmus M., Aurias A., Pedeutour F., Mathoulin-Pelissier S., and Coindre J.M. Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas. J. Pathol. 202 1 (2004) 95-102
15. Kawaguchi K., Oda Y., Saito T., Yamamoto H., Tamiya S., Takahira T., Miyajima K., Iwamoto Y., and Tsuneyoshi M. Mechanisms of inactivation of the p16INK4a gene in leiomyosarcoma of soft tissue: decreased p16 expression correlates with promoter methylation and poor prognosis. J. Pathol. 201 3 (2003) 487-495
16. Kubbutat M.H., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 6630 (1997) 299-303
17. Midgley C.A., Desterro J.M., Saville M.K., Howard S., Sparks A., Hay R.T., and Lane D.P. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19 19 (2000) 2312-2323
18. Oda Y., Yamamoto H., Takahira T., Kobayashi C., Kawaguchi K., Tateishi N., Nozuka Y., Tamiya S., Tanaka K., Matsuda S., Yokoyama R., Iwamoto Y., and Tsuneyoshi M. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis. J. Pathol. 207 4 (2005) 410-421
19. Pilotti S., Della Torre G., Lavarino C., Di Palma S., Sozzi G., Minoletti F., Rao S., Pasquini G., Azzarelli A., Rilke F., and Pierotti M.A. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J. Pathol. 181 1 (1997) 14-24
20. Rocco J.W., and Sidransky D. p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp. Cell Res. 264 1 (2001) 42-55 (Review)
21. Ropke M., Boltze C., Neumann H.W., Roessner A., and Schneider-Stock R. Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma. Pathol. Res. Pract. 199 6 (2003) 437-444
22. Sakamoto A., Oda Y., Adachi T., Saito T., Tamiya S., Iwamoto Y., and Tsuneyoshi M. Beta-catenin accumulation and gene mutation in exon 3 in dedifferentiated liposarcoma and malignant fibrous histiocytoma. Arch. Pathol. Lab. Med. 126 9 (2002) 1071-1078
23. Sakamoto A., Oda Y., Adachi T., Tamiya S., Matsuda S., Tanaka K., Iwamoto Y., and Tsuneyoshi M. H-ras oncogene mutation in dedifferentiated liposarcoma. Polymerase chain reaction-restriction fragment length polymorphism analysis,. Am. J. Clin. Pathol. 115 2 (2001) 235-242
24. Sandberg A.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet. Cytogenet. 155 1 (2004) 1-24 (Review)
25. Schneider-Stock R., Walter H., Radig K., Rys J., Bosse A., Kuhnen C., Hoang-Vu C., and Roessner A. MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas. J. Cancer. Res. Clin. Oncol. 124 10 (1998) 532-540
26. Segura-Sanchez J., Gonzalez-Campora R., Pareja-Megia M.J., Garcia-Escudero A., Galera-Ruiz H., and Lopez-Beltran A. Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma. Anticancer Res. 26 6C (2006) 4937-4942
27. Seidel C., Bartel F., Rastetter M., Bluemke K., Wurl P., Taubert H., and Dammann R. Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int. J. Cancer 114 3 (2005) 442-447
28. Shimoji T., Kanda H., Kitagawa T., Kadota K., Asai R., Takahashi K., Kawaguchi N., Matsumoto S., Hayashizaki Y., Okazaki Y., and Shinomiya K. Clinico-molecular study of dedifferentiation in well-differentiated liposarcoma. Biochem. Biophys. Res. Commun. 314 4 (2004) 1133-1140
29. Szymanska J., Mandahl N., Mertens F., Tarkkanen M., Karaharju E., and Knuutila S. Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13-15: a combined cytogenetic and comparative genomic hybridization study. Genes Chromosomes Cancer 16 1 (1996) 31-34
30. Takahira T., Oda Y., Tamiya S., Yamamoto H., Kobayashi C., Izumi T., Ito K., Iwamoto Y., and Tsuneyoshi M. Alterations of the RB1 gene in dedifferentiated liposarcoma. Mod. Pathol. 18 11 (2005) 1461-1470
31. Weiss S.W. Lipomatous tumors. Monogr. Pathol. 38 (1996) 207-239 (Review)
32. Wong D.J., Foster S.A., Galloway D.A., and Reid B.J. Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol. Cell. Biol. 19 8 (1999) 5642-5651
33. Xu J., Yang G., Bu H., Guo L., Zhang S., and Liu J. Detection of methylation status of p16 tumor suppressor gene in soft tissue leiomyosarcoma. Zhonghua Bing Li Xue Za Zhi 30 1 (2001) 16-18